Radiopharm Theranostics Ltd has released a press release.
RAD Integrins technology featured in Cancers journal
Filed with ASX ·
6ix hasn’t read this filing yet.
Radiopharm Theranostics Limited on 6ix
Later from Radiopharm Theranostics
- RAD acquires IP Ownership of Radiopharmaceutical Nanobodies
- Radiopharm and TerraPower sign Actinium 225 agreement
- LOI with GenesisCare to start first trial in Australia
- RAD Licenses UCLA Dual Action Antibody
- FDA grants Orphan drug status to RAD DUNP19 for Osteosarcoma
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics